Drug Profile
Lutetium-177 oxodotreotide - Advanced Accelerator Applications
Alternative Names: 177Lu-DOTA-TATE; 177Lu-DOTA0-Tyr3-Octreotate; 177Lu-labelled somatostatin analog peptide; [177Lu]Lu-DOTA-TATE; [Lu-177]-Dota-Tyr3-Octreotate; [Lu-177]-DOTATATE; AAA 601; F-1515; Lu-177-octreotate; Lu-DOTATATE; Lutate; Lutathera; LUTETIUM (177LU) OXODOTREOTIDE; Lutetium (177Lu) oxodotreotide - Advanced Accelerator Applications; Lutetium Lu 177 dotatate; lutetium Lu 177 dotatate; Lutetium-177-DOTA-Tyr-3-octreotate; Lutetium-177-DOTATATE; Octreotate Lu-177 DOTA Tyr-3; Octreotate-Lu-177Latest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator BioSynthema
- Developer Advanced Accelerator Applications; Australasian Gastro-Intestinal Trials Group; FUJIFILM Toyama Chemical; Georgetown University Medical Center; Gustave Roussy; King Faisal Specialist Hospital & Research Centre; National Cancer Centre (Singapore); National Cancer Institute (USA); Novartis Pharmaceuticals; NYU Langone Medical Center; Peking University; University Medical Center Utrecht
- Class Antineoplastics; Peptides; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuroendocrine tumours
- Phase II Glioblastoma; Meningioma; Nasopharyngeal cancer; Pancreatic cancer; Paraganglioma; Phaeochromocytoma; Small cell lung cancer
Most Recent Events
- 19 Jan 2024 Efficacy and adverse events data from the phase III NETTER-2 trial in Neuroendocrine tumours released by Novartis
- 18 Jan 2024 Efficacy and adverse events data from the phase III NETTER-2 trial in Neuroendocrine tumours presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 08 Jan 2024 Novartis plans to file first regulatory application for Gastroenteropancreatic neuroendocrine tumours (First-line therapy) in the European Union in 2024 (Novartis pipeline, February 2024)